2025年3月3日 · At Syndax, we are advancing the next generation of targeted treatments with the goal of realizing a future in which people with cancer live longer and better than ever before. …

Syndax anticipates submitting a supplemental NDA (sNDA) based on this positive data from the pivotal AUGMENT-101 trial of revumenib in adults and pediatric patients with NPM1m AML in …

Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and …

Find the latest Syndax Pharmaceuticals, Inc. (SNDX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A …

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include …

2024年11月12日 · Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline …

2025年2月25日 · Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the …

2024年11月15日 · The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood …

2024年11月12日 · Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today …